Zynerba rises on positive mid-stage data from genetic disorder trial

Zynerba Pharmaceuticals

17/10/2022 13:56

** Shares of drug developer Zynerba Pharmaceuticals  ZYNE.O 
jump ~9% to 75 cents before the bell 
    ** Co says its treatment, Zygel, for behavioral symptoms in
children and adolescents with 22q11.2 deletion syndrome showed a
positive risk-benefit profile in a mid-stage study  urn:newsml:reuters.com:*:nGNX3NBvl9
    ** 22q11.2 deletion syndrome, also known as DiGeorge
syndrome, is a condition in which a part of the chromosome 22 is
missing and can result in various developmental problems
    ** ZYNE says Zygel showed statistically significant
improvement in anxiety-related and behavioral symptoms over
first 14-week treatment period 
    ** Three patients reported mild application-site adverse
events related to Zygel; one patient discontinued treatment due
to non-Zygel related adverse events, says ZYNE
    ** Co will be discussing Zygel's regulatory path with the
U.S. Food and Drug Administration in second half of this year   
 
    ** As of last close, stock down 75% YTD
 (Reporting by Bhanvi Satija in Bengaluru)
 ((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91
9873062788;))